We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bristol-Myers Squibb and Samsung BioLogics Announce Biopharmaceutical Manufacturing Relationship
News

Bristol-Myers Squibb and Samsung BioLogics Announce Biopharmaceutical Manufacturing Relationship

Bristol-Myers Squibb and Samsung BioLogics Announce Biopharmaceutical Manufacturing Relationship
News

Bristol-Myers Squibb and Samsung BioLogics Announce Biopharmaceutical Manufacturing Relationship

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bristol-Myers Squibb and Samsung BioLogics Announce Biopharmaceutical Manufacturing Relationship"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Financial terms were not disclosed. Technology transfer and trial production will commence in July 2013 and commercial production will immediately begin following regulatory approvals.

"We are pleased to announce this strategic manufacturing relationship with Bristol-Myers Squibb and look forward to delivering best-in-class manufacturing services with the highest global quality standards," said Tae-Han Kim, president and CEO of Samsung BioLogics. “The relationship with Bristol-Myers Squibb represents the validation of our long-term commitment to the biopharmaceutical manufacturing industry.”

"Our agreement with Samsung is an important part of our company’s overall manufacturing and supply strategy focused on creating long-term relationships with high quality manufacturing partners around the world,” said Louis Schmukler, president, Global Manufacturing & Supply, Bristol-Myers Squibb. “This agreement increases our biologic manufacturing capacity to help ensure sufficient long-term supply of our commercial products.”

Advertisement